RSC Pharmaceutics Blog

RSC Pharmaceutics has published its first articles. To celebrate this, we asked the authors to discuss their work in some more detail.

In this edition, we hear from Scott Mitchell about their study titled Acid- and base-resistant antimicrobial hydrogels based on polyoxometalates and chitosan.

“Only a few decades ago, antimicrobial resistance (AMR) was largely confined to hospitals and long-term care facilities, but over the last decade it has emerged as a serious global threat to public health. Furthermore, invasive fungal infections kill more than 1.7 million and affect over a billion people each year; however, their devastating impact on human health is not yet widely appreciated and is frequently neglected by public health authorities. In our group, we’ve used the naturally occurring polymer chitosan (CS) in combination with molecular polyoxometalates (POMs) to produce hybrid micro- and nano-capsules. Our hypothesis was that such nanostructured hybrid hydrogel materials could possess surface-active biocidal activity through additive and synergic effects. A series of pH resistance assays concluded that macroscopic hybrid hydrogels made from POMs and chitosan maintained their structural integrity after prolonged contact with both acidic and basic pH and that their potent surface-active antibiofilm properties against model bacterial strains (Gram-positive Bacillus subtilis and Gram-negative Escherichia coli) and airborne environmental moulds (Aspergillus niger and Cladosporium cladosporioides). Furthermore, the antimicrobial activity of the hydrogels could be enhanced through the inclusion of naturally occurring antimicrobial agents such as eugenol and cinnamaldehyde into the polymeric matrix.”

“Although we anticipated some form of antifungal activity, we didn’t anticipate these hybrid POM@CS hydrogels to perform so well in these preliminary tests against moulds. So, modulating this synergistic activity and improving the specificity towards certain strains is something that we’re really excited about.”

“The most challenging aspect was probably related to the transfer of synthetic procedures used to make the materials from one researcher to another. The project was initiated by Isabel Franco (a doctoral researcher) and Andrés Seral (a postdoctoral researcher), both of whom found positions in industry and academia after their contracts ended. This meant they had to transfer the synthetic protocols to Callum McWilliams (an Erasmus student from University of Glasgow) who completed the work during his research project in Zaragoza. Although it wasn’t an ideal scenario, we now know that the synthetic protocols are highly reproducible from one person to another and that’s definitely a positive outcome.”

“Ultimately, we hope that such synergic approaches could help to prevent the appearance of resistances. These hydrogels could easily be employed in health settings, as wound healing patches or poultices. However, there are many other instances where microbial colonization must be treated or avoided and where the appearance of resistances is troubling, e.g., biofilm build-up and blockages in water purification systems or microbiologically-influenced corrosion of engineered structures.”

Want to know more about their work? Read the full paper here!

Acid- and base-resistant antimicrobial hydrogels based on polyoxometalates and chitosan

Callum McWilliams, Isabel Franco-Castillo, Andrés Seral Ascaso, Sonia García-Embid, Mariella Malefioudaki, Johann G. Meier, Rafael Martín-Rapún and Scott G. Mitchell

RSC Pharm. 2024, Advance Article, DOI: 10.1039/D4PM00062E

RSC Pharmaceutics provides researchers with a platform to publish research in pharmaceutics and advance this field. We are interested in any submission that shares new scientific findings across chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery.   Find out more about the journal Read our published articles Submit your manuscript today Sign up for email alerts Follow us on social media

RSC Pharmaceutics has published its first articles. To celebrate this, we asked the authors to discuss their work in some more detail.

In this edition, we hear from Noriho Kamiya about their study titled Exploring the molecular structure of lipids in the design of artificial lipidated antifungal proteins.

“This study follows on from our previous work (ACS Infect. Dis., 2022, 8, 1051-1061). In our attempts to enhance the function of antifungal proteins by artificial lipid modification, we have obtained new evidence that specific lengths of lipid moieties enhance the antifungal activity of the chitin-binding domain of a plant chitinase in the presence of amphotericin B. Further studies, including the development of new formulations that maximize the potent antifungal properties, are underway.”

Want to know more about their work? Read the full paper here!

Exploring the molecular structure of lipids in the design of artificial lipidated antifungal proteins

Hendra Saputra, Muhammad Safaat, Kazuki Uchida, Pugoh Santoso, Rie Wakabayashi, Masahiro Goto, Toki Taira and Noriho Kamiya

RSC Pharm. 2024, Advance Article, DOI: 10.1039/D3PM00087G

RSC Pharmaceutics provides researchers with a platform to publish research in pharmaceutics and advance this field. We are interested in any submission that shares new scientific findings across chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery.   Find out more about the journal Read our published articles Submit your manuscript today Sign up for email alerts Follow us on social media

RSC Pharmaceutics has published its first articles. To celebrate this, we asked the authors to discuss their work in some more detail.

In this edition, we hear from Venkatesh Ravula about their Review titled Phenylboronic acid-derived nanovectors for gene/drug delivery by targeting cell surface glycans.

Want to know more about their work? Read the full paper here!

Phenylboronic acid-derived nanovectors for gene/drug delivery by targeting cell surface glycans

Venkanna Muripiti, Venkatesh Ravula, Srinivas Batthula, Janardhan Banothu and Ramesh Gondru

RSC Pharm. 2024, Advance Article, DOI: 10.1039/D4PM00005F

RSC Pharmaceutics provides researchers with a platform to publish research in pharmaceutics and advance this field. We are interested in any submission that shares new scientific findings across chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery. Find out more about the journal Read our published articles Submit your manuscript today Sign up for email alerts Follow us on social media

RSC Pharmaceutics recently published its first articles, which can be read for free here. To celebrate publishing our first articles, we asked some of our authors to discuss their work in more detail.

In this post, we hear about the research from Chvíla et al. in their article titled “A zuranolone nanocrystal formulation enables solubility-independent in vivo study of pentylenetetrazol-induced seizures in a rat model”. Watch three of the authors, Eva Kudová, Stanislav Chvíla and František Štěpánek, talk about their work below or here!

A zuranolone nanocrystal formulation enables solubility-independent in vivo study of pentylenetetrazol-induced seizures in a rat model Stanislav Chvíla, Hana Kubová, Pavel Mareš, Eva Kudová and František Štěpánek RSC Pharm., 2024, Advance Article. DOI: 10.1039/D3PM00043E

RSC Pharmaceutics provides researchers with a platform to publish research in pharmaceutics and advance this field. We are interested in any submission that shares new scientific findings across chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery. Sign up for email alerts and submit your manuscript.